# Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

> **NCT00728780** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- Adverse Events
- Pharmacokinetic Variables

## Interventions

- **DRUG:** ABT-143
- **DRUG:** ABT-335 and rosuvastatin

## Key facts

- **NCT ID:** NCT00728780
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2008-09
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00728780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00728780, "Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00728780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*